Co-administration of empagliflozin and metformin provided the greatest benefits, such that the diabetes-induced upregulation of all genes was no longer present in this group, except for Ctgf expression which remained elevated compared to non-diabetic levels (Fig. 9a–e). The gene discussed is CCN2; the disease is diabetes mellitus.